Main Industry
Biotechnology
Main Product/Service
Our therapy involves genetically modifying a patient’s T cells outside the patient’s body, transforming the T cells to express chimeric antigen receptors (CARs), and then reinfusing the engineered T cells back into the patient.
Founded Year
2020
Unified Business No.
83304134
Status
Active
Number of Employees
23
Total Paid-in
Capital
200,605,000 (NT$)
Location of Company
Taiwan
, New Taipei City
Exit Status
Emerging Stock Exchange(2026)
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
UWELL BioPharma, is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotheraputics designed to harness the power of a patient’s own immune system to target and eradicate cancer cells. We do this using our engineered autologous cell therapy, which we believe is a transformational approach to the treatment of cancer. Our therapy involves genetically modifying a patient’s T cells outside the patient’s body, transforming the T cells to express chimeric antigen receptors (CARs), and then reinfusing the engineered T cells back into the patient. CARs can recognize native cancer antigens that are part of an intact protein presented on the cancer cell surface. UWELL BioPharma is a cellular therapy company based in New Taipei City, Taiwan. UWELL has a strong management team and a team of professional and experienced scientists who are developing cutting edge technology to help fight cancer. Uwell Has a strong collaboration and close interaction with excellent clinical teams and partners in Taiwan and China, as well as in Malaysia. UWELL has generated and advanced a broad portfolio of product candidates to target hematological tumors.
